Loading clinical trials...
Loading clinical trials...
A Phase I, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Clinical Study to Assess the Safety, Tolerability and Pharmacokinetics of HEC113995 PA•H2O Tablets in Healthy Subjects
Conditions
Interventions
HEC113995 PA•H2O tablets
Placebo tablets
Locations
1
China
Shanghai Xuhui Central Hospital
Shanghai, China
Start Date
July 4, 2019
Primary Completion Date
December 6, 2019
Completion Date
December 6, 2019
Last Updated
October 28, 2020
NCT07115329
NCT06793397
NCT07025720
NCT06780917
NCT04480918
NCT06878859
Lead Sponsor
Sunshine Lake Pharma Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions